Please assess the completion status of the following clinical trial:

Trial Title: An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent from the subject and/or a legal representative prior to initiation of any study-mandated procedures.~* Subjects who have completed Week 52 of the parent AC-055H301/RUBATO DB study (NCT03153137)~* Women of childbearing potential must:~  1. have a negative serum pregnancy test prior to first intake of OL study drug, and,~ 2. agree to perform monthly pregnancy tests up to the end of the safety follow up (S-FU) period, and,~ 3. use reliable methods of contraception from enrollment up to at least 30 days after study treatment discontinuation.~Exclusion Criteria:~* Clinical worsening leading to medical interventions including reoperation of Fontan circulation (Fontan take-down) during the enrollment period~* Systolic blood pressure \< 90 mmHg (\< 85 mmHg for subjects \< 18 years old and \< 150 cm of height) at rest~* Criteria related to macitentan use~* Any known factor or disease that may interfere with treatment compliance or full participation in the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label treatment period (Type: EXPERIMENTAL): oral administration of 10 mg macitentan once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).